Joanna Vergidis
Overview
Explore the profile of Joanna Vergidis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
570
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fonseca N, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha A, et al.
Nat Commun
. 2024 Feb;
15(1):1828.
PMID: 38418825
No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratification...
2.
Soleimani M, Zou K, Sunderland K, Struss W, Eigl B, Nappi L, et al.
Eur J Cancer
. 2021 Jun;
152:215-222.
PMID: 34130153
Background: Metastatic castration-resistant prostate cancer (mCRPC) disproportionately affects the elderly. There is limited data assessing the efficacy and tolerability of abiraterone acetate (AA) versus enzalutamide in this population. Objective: To...
3.
Annala M, Taavitsainen S, Khalaf D, Vandekerkhove G, Beja K, Sipola J, et al.
Clin Cancer Res
. 2021 Jun;
27(16):4610-4623.
PMID: 34083234
Purpose: Cross-resistance renders multiple lines of androgen receptor (AR) signaling inhibitors increasingly futile in metastatic castration-resistant prostate cancer (mCRPC). We sought to determine acquired genomic contributors to cross-resistance. Experimental Design:...
4.
Khalaf D, Annala M, Taavitsainen S, Finch D, Oja C, Vergidis J, et al.
Lancet Oncol
. 2019 Nov;
20(12):1730-1739.
PMID: 31727538
Background: Abiraterone acetate plus prednisone and enzalutamide are both used for the treatment of metastatic castration-resistant prostate cancer. We aimed to determine the best sequence in which to use both...
5.
Khalaf D, Sunderland K, Eigl B, Kollmannsberger C, Ivanov N, Finch D, et al.
Eur Urol
. 2018 Dec;
75(6):940-947.
PMID: 30591354
Background: Abiraterone and enzalutamide are associated with side effects that may impair health-related quality of life (HRQoL). Objective: To assess patient-reported HRQoL, depression symptoms, and cognitive function for abiraterone versus...
6.
Lavoie J, Zou K, Khalaf D, Eigl B, Kollmannsberger C, Vergidis J, et al.
Prostate
. 2018 Oct;
79(3):281-287.
PMID: 30370697
Background: Adding docetaxel to androgen deprivation therapy (ADT) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) has known efficacy, with an overall survival benefit in Phase III clinical trials....
7.
Chedgy E, Vandekerkhove G, Herberts C, Annala M, Donoghue A, Sigouros M, et al.
J Pathol
. 2018 Jul;
246(2):244-253.
PMID: 30015382
Small-cell prostate carcinoma (SCPC) is an aggressive malignancy that is managed similarly to small-cell lung cancer. SCPC can evolve from prostate adenocarcinoma in response to androgen deprivation therapy, but, in...
8.
Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner E, et al.
Cancer Discov
. 2018 Jan;
8(4):444-457.
PMID: 29367197
Primary resistance to androgen receptor (AR)-directed therapies in metastatic castration-resistant prostate cancer (mCRPC) is poorly understood. We randomized 202 patients with treatment-naïve mCRPC to abiraterone or enzalutamide and performed whole-exome...
9.
Kalina J, Neilson D, Comber A, Rauw J, Alexander A, Vergidis J, et al.
Cancers (Basel)
. 2017 Jan;
9(2).
PMID: 28134800
Prostate cancer patients often receive androgen deprivation therapy (ADT) in combination with radiation therapy (RT). Recent evidence suggests that both ADT and RT have immune modulatory properties. First, ADT can...
10.
Vergidis J, Gresham G, Lim H, Renouf D, Kennecke H, Ruan J, et al.
Clin Colorectal Cancer
. 2015 Aug;
15(1):16-23.
PMID: 26281943
Background: Weight modification after a diagnosis of colon cancer and its impact on outcomes remain unclear. Thus we aimed to examine the association of obesity and weight changes from baseline...